Raadpleeg ook literatuurlijsten niet-toxische middelen en behandelingen als preventie van arts-bioloog drs. engelbert Valstar.

21 november 2020: JAMA online 18 november 2020

Vitamine D-suppletie geeft een vermindering van het ontstaan van gevorderde uitgezaaide vormen van kanker. De sterkste afname werd waargenomen bij mensen met een normaal gewicht, volgens een studie die online is gepubliceerd op 18 november online bij JAMA Network Open.

Paulette D. Chandler, MD, MPH, van de Harvard Medical School in Boston, en collega's hebben een follow-up uitgevoerd naar de mogelijke vermindering van het aantal sterfgevallen door kanker die werd gezien in de vitamine D- en omega-3-studie (zie dit artikel) om te onderzoeken of vitamine D de incidentie van gevorderde kanker verminderde en mogelijke beïnvloeding door een body mass index (BMI). De primaire uitkomst voor deze analyse was een samengestelde incidentie van uitgezaaide en fatale invasieve vormen van kanker.

De onderzoekers ontdekten dat deelnemers die willekeurig werden toegewezen aan of vitamine D of een placebo een statistisch significante vermindering van gevorderde vormen van kanker hadden bij de dianose (uitgezaaid of fataal); 1,7 procent van de 12.927 patiënten uit de vitamine D groep hadden een uitgezaaide vorm van kanker of overlden aan hun kanker, versus 2,1 procent van de 12.944 patiënten uit de placebogroep; hazard ratio, 0,83) .

Bij stratificatie op basis van het BMI werd de afname van incidentele uitgezaaide of fatale kanker gezien voor de vitamine D groep onder degenen met een normale BMI (BMI <25 kg / m2: hazard ratio, 0,62), maar niet statistisch significant bij degenen met overgewicht of obesitas.

Uit het studierapport: 

Findings  In this secondary analysis of a randomized clinical trial with 25 871 patients, supplementation with vitamin D3 reduced the incidence of advanced (metastatic or fatal) cancer in the overall cohort, with strongest risk reduction in individuals with normal weight and no reduction among individuals with overweight or obesity.

Het studierapport is gratis in te zien in JAMA online, hier het abstract van de studie: 

November 18, 2020

Effect of Vitamin D3 Supplements on Development of Advanced CancerA Secondary Analysis of the VITAL Randomized Clinical Trial

Paulette D. Chandler, MD, MPH1; Wendy Y. Chen, MD, MPH2,3; Oluremi N. Ajala, MD, MPH1; et alAditi Hazra, PhD, MPH1; Nancy Cook, ScD1; Vadim Bubes, PhD1; I-Min Lee, MBBS, ScD1; Edward L. Giovannucci, MD, ScD3,4,5; Walter Willett, MD, DrPH3,4,5; Julie E. Buring, ScD1,5; JoAnn E. Manson, MD, DrPH1,3,5; for the VITAL Research Group
Author Affiliations Article Information
JAMA Netw Open. 2020;3(11):e2025850. doi:10.1001/jamanetworkopen.2020.25850

Key Points

Question  Does vitamin D3 supplementation reduce the risk of developing advanced (metastatic or fatal) cancer among adults without a diagnosis of cancer at baseline?

Findings  In this secondary analysis of a randomized clinical trial with 25 871 patients, supplementation with vitamin D3 reduced the incidence of advanced (metastatic or fatal) cancer in the overall cohort, with strongest risk reduction in individuals with normal weight and no reduction among individuals with overweight or obesity.

Meaning  These findings suggest that vitamin D3 may reduce the risk of developing advanced cancer among adults without a diagnosis of cancer at baseline; this protective effect is apparent for those who have normal but not elevated body mass index.

Abstract

Importance  Epidemiologic and trial data suggest that vitamin D supplementation may reduce metastatic cancer and cancer mortality, reflecting shared biological pathways.

Objective  To follow up on the possible reduction in cancer death in the Vitamin D and Omega-3 Trial (VITAL) with an evaluation of whether vitamin D reduces the incidence of advanced (metastatic or fatal) cancer and an examination possible effect modification by body mass index.

Design, Setting, and Participants  VITAL is a randomized, double-blind, placebo-controlled, 2 × 2 factorial clinical trial of vitamin D3 (cholecalciferol, 2000 IU/d) and marine omega-3 fatty acids (1 g/d). This multicenter clinical trial was conducted in the United States; participants included men aged 50 years or older and women aged 55 years or older who were free of cancer and cardiovascular disease at baseline. Randomization took place from November 2011 through March 2014, and study medication ended on December 31, 2017. Data for this secondary analysis were analyzed from November 1, 2011, to December 31, 2017.

Interventions  Vitamin D3 (cholecalciferol, 2000 IU/d) and marine omega-3 fatty acids (1 g/d) supplements.

Main Outcomes and Measures  For the present analysis, the primary outcome was a composite incidence of metastatic and fatal invasive total cancer, because the main VITAL study showed a possible reduction in fatal cancer with vitamin D supplementation and effect modification by body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) for total cancer incidence reduction for individuals with normal BMI, but not for individuals with overweight or obesity. Secondary analyses included examination of BMI (<25, 25 to < 30, and ≥30) as effect modifiers of the observed associations.

Results  Among 25 871 randomized VITAL participants (51% female; mean age, 67.1 [7.1] years), 1617 were diagnosed with invasive cancer over a median intervention period of 5.3 years (range, 3.8-6.1 years). As previously reported, no significant differences for cancer incidence by treatment arm were observed. However, a significant reduction in advanced cancers (metastatic or fatal) was found for those randomized to vitamin D compared with placebo (226 of 12 927 assigned to vitamin D [1.7%] and 274 of 12 944 assigned to placebo [2.1%]; HR, 0.83 [95% CI, 0.69-0.99]; P = .04). When stratified by BMI, there was a significant reduction for the vitamin D arm in incident metastatic or fatal cancer among those with normal BMI (BMI<25: HR, 0.62 [95% CI, 0.45-0.86]) but not among those with overweight or obesity (BMI 25-<30: HR, 0.89 [95% CI, 0.68-1.17]; BMI≥30: HR, 1.05 [95% CI, 0.74-1.49]) (P = .03 for interaction by BMI).

Conclusions and Relevance  In this randomized clinical trial, supplementation with vitamin D reduced the incidence of advanced (metastatic or fatal) cancer in the overall cohort, with the strongest risk reduction seen in individuals with normal weight.

Trial Registration  ClinicalTrials.gov Identifier: NCT01169259

References
1.
Keum  N, Lee  DH, Greenwood  DC, Manson  JE, Giovannucci  E.  Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials.   Ann Oncol. 2019;30(5):733-743. doi:10.1093/annonc/mdz059PubMedGoogle ScholarCrossref
2.
Zhang  Y, Fang  F, Tang  J,  et al.  Association between vitamin D supplementation and mortality: systematic review and meta-analysis.   BMJ. 2019;366:l4673. doi:10.1136/bmj.l4673PubMedGoogle ScholarCrossref
3.
Feldman  D, Krishnan  AV, Swami  S, Giovannucci  E, Feldman  BJ.  The role of vitamin D in reducing cancer risk and progression.   Nat Rev Cancer. 2014;14(5):342-357. doi:10.1038/nrc3691PubMedGoogle ScholarCrossref
4.
Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Ross  AC, Taylor  CL, Yaktine  AL, Del Valle  HB, eds.  Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011.
5.
Keum  N, Giovannucci  E.  Vitamin D supplements and cancer incidence and mortality: a meta-analysis.   Br J Cancer. 2014;111(5):976-980. doi:10.1038/bjc.2014.294PubMedGoogle ScholarCrossref
6.
Manson  JE, Cook  NR, Lee  IM,  et al; VITAL Research Group.  Vitamin D supplements and prevention of cancer and cardiovascular disease.   N Engl J Med. 2019;380(1):33-44. doi:10.1056/NEJMoa1809944PubMedGoogle ScholarCrossref
7.
Martineau  AR, Jolliffe  DA, Hooper  RL,  et al.  Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.   BMJ. 2017;356:i6583. doi:10.1136/bmj.i6583PubMedGoogle ScholarCrossref
8.
Formenti  AM, Tecilazich  F, Frara  S, Giubbini  R, De Luca  H, Giustina  A.  Body mass index predicts resistance to active vitamin D in patients with hypoparathyroidism.   Endocrine. 2019;66(3):699-700. doi:10.1007/s12020-019-02105-6PubMedGoogle ScholarCrossref
9.
Guzik  TJ, Skiba  DS, Touyz  RM, Harrison  DG.  The role of infiltrating immune cells in dysfunctional adipose tissue.   Cardiovasc Res. 2017;113(9):1009-1023. doi:10.1093/cvr/cvx108PubMedGoogle ScholarCrossref
10.
Martí  A, Marcos  A, Martínez  JA.  Obesity and immune function relationships.   Obes Rev. 2001;2(2):131-140. doi:10.1046/j.1467-789x.2001.00025.xPubMedGoogle ScholarCrossref
11.
Bähr  I, Jahn  J, Zipprich  A, Pahlow  I, Spielmann  J, Kielstein  H.  Impaired natural killer cell subset phenotypes in human obesity.   Immunol Res. 2018;66(2):234-244. doi:10.1007/s12026-018-8989-4PubMedGoogle ScholarCrossref
12.
Lee  GY, Park  CY, Cha  KS, Lee  SE, Pae  M, Han  SN.  Differential effect of dietary vitamin D supplementation on natural killer cell activity in lean and obese mice.   J Nutr Biochem. 2018;55:178-184. doi:10.1016/j.jnutbio.2018.01.004PubMedGoogle ScholarCrossref
13.
Woodall  MJ, Neumann  S, Campbell  K, Pattison  ST, Young  SL.  The effects of obesity on anti-cancer immunity and cancer immunotherapy.   Cancers (Basel). 2020;12(5):E1230. doi:10.3390/cancers12051230PubMedGoogle Scholar
14.
Cuyàs  E, Verdura  S, Martin-Castillo  B,  et al.  Tumor cell-intrinsic immunometabolism and precision nutrition in cancer immunotherapy.   Cancers (Basel). 2020;12(7):E1757. doi:10.3390/cancers12071757PubMedGoogle Scholar
15.
Wang  Z, Aguilar  EG, Luna  JI,  et al.  Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.   Nat Med. 2019;25(1):141-151. doi:10.1038/s41591-018-0221-5PubMedGoogle ScholarCrossref
16.
Abbas  MA.  Physiological functions of Vitamin D in adipose tissue.   J Steroid Biochem Mol Biol. 2017;165(Pt B):369-381. doi:10.1016/j.jsbmb.2016.08.004Google Scholar
17.
Schulz  KF, Altman  DG, Moher  D, CONSORT Group.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.   Ann Intern Med. 2010;152(11):726-732. doi:10.7326/0003-4819-152-11-201006010-00232PubMedGoogle ScholarCrossref
18.
Fritz  AG, Percy  C, Jack  A,  et al  International Classification of Diseases for Oncology (ICD-O), Third Edition. Geneva: World Health Organization; 2000.
19.
Ng  K, Nimeiri  HS, McCleary  NJ,  et al.  Effect of high-dose vs standard-dose vitamin D3 supplementation on progression-free survival among patients with advanced or metastatic colorectal cancer: the SUNSHINE randomized clinical trial.   JAMA. 2019;321(14):1370-1379. doi:10.1001/jama.2019.2402
ArticlePubMedGoogle ScholarCrossref
20.
Urashima  M, Ohdaira  H, Akutsu  T,  et al.  Effect of vitamin D supplementation on relapse-free survival among patients with digestive tract cancers: the AMATERASU randomized clinical trial.   JAMA. 2019;321(14):1361-1369. doi:10.1001/jama.2019.2210
ArticlePubMedGoogle ScholarCrossref
21.
Díaz  GD, Paraskeva  C, Thomas  MG, Binderup  L, Hague  A.  Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy.   Cancer Res. 2000;60(8):2304-2312.PubMedGoogle Scholar
22.
Scaglione-Sewell  BA, Bissonnette  M, Skarosi  S, Abraham  C, Brasitus  TA.  A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1.   Endocrinology. 2000;141(11):3931-3939. doi:10.1210/endo.141.11.7782PubMedGoogle ScholarCrossref
23.
Holick  MF.  Vitamin D deficiency.   N Engl J Med. 2007;357(3):266-281. doi:10.1056/NEJMra070553PubMedGoogle ScholarCrossref
24.
Han  J, Guo  X, Yu  X,  et al.  25-hydroxyvitamin D and total cancer incidence and mortality: a meta-analysis of prospective cohort studies.   Nutrients. 2019;11(10):E2295. doi:10.3390/nu11102295PubMedGoogle Scholar
25.
Yuan  C, Sato  K, Hollis  BW,  et al. Plasma 25-hydroxyvitamin D levels and survival in patients with advanced or metastatic colorectal cancer: findings from CALGB/SWOG 80405 (Alliance).  Clin Cancer Res. 2019;25(24):7497-7505. doi:10.1158/1078-0432.CCR-19-0877
26.
Kennel  KA, Drake  MT.  Vitamin D in the cancer patient.   Curr Opin Support Palliat Care. 2013;7(3):272-277. doi:10.1097/SPC.0b013e3283640f74PubMedGoogle ScholarCrossref
27.
Alkan  A, Köksoy  EB.  Vitamin D deficiency in cancer patients and predictors for screening (D-ONC study).   Curr Probl Cancer. 2019;43(5):421-428. doi:10.1016/j.currproblcancer.2018.12.008PubMedGoogle ScholarCrossref
28.
Jung  YS, Wu  D, Smith  D, Meydani  SN, Han  SN.  Dysregulated 1,25-dihydroxyvitamin D levels in high-fat diet-induced obesity can be restored by changing to a lower-fat diet in mice.   Nutr Res. 2018;53:51-60. doi:10.1016/j.nutres.2018.03.008PubMedGoogle ScholarCrossref
29.
Wortsman  J, Matsuoka  LY, Chen  TC, Lu  Z, Holick  MF.  Decreased bioavailability of vitamin D in obesity.   Am J Clin Nutr. 2000;72(3):690-693. doi:10.1093/ajcn/72.3.690PubMedGoogle ScholarCrossref
30.
Drincic  AT, Armas  LA, Van Diest  EE, Heaney  RP.  Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity.   Obesity (Silver Spring). 2012;20(7):1444-1448. doi:10.1038/oby.2011.404PubMedGoogle ScholarCrossref
31.
Kim  H, Chandler  P, Ng  K, Manson  JE, Giovannucci  E.  Obesity and efficacy of vitamin D3 supplementation in healthy black adults.   Cancer Causes Control. 2020;31(4):303-307. doi:10.1007/s10552-020-01275-3PubMedGoogle ScholarCrossref
32.
Moslehi  N, Shab-Bidar  S, Mirmiran  P, Hosseinpanah  F, Azizi  F.  Determinants of parathyroid hormone response to vitamin D supplementation: a systematic review and meta-analysis of randomised controlled trials.   Br J Nutr. 2015;114(9):1360-1374. doi:10.1017/S0007114515003189PubMedGoogle ScholarCrossref
33.
Lotito  A, Teramoto  M, Cheung  M, Becker  K, Sukumar  D.  Serum parathyroid hormone responses to vitamin D supplementation in overweight/obese adults: a systematic review and meta-analysis of randomized clinical trials.   Nutrients. 2017;9(3):E241. doi:10.3390/nu9030241PubMedGoogle Scholar
34.
Rothwell  PM, Cook  NR, Gaziano  JM,  et al.  Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.   Lancet. 2018;392(10145):387-399. doi:10.1016/S0140-6736(18)31133-4PubMedGoogle ScholarCrossref
35.
Bassuk  SS, Manson  JE, Lee  IM,  et al.  Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL).   Contemp Clin Trials. 2016;47:235-243. doi:10.1016/j.cct.2015.12.022PubMedGoogle ScholarCrossref
36.
Haidari  F, Abiri  B, Iravani  M,  et al.  Effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer: a study protocol for a double blind randomized controlled trial.   Trials. 2019;20(1):682. doi:10.1186/s13063-019-3719-3PubMedGoogle ScholarCrossref

.

preventie, vitamin D3 (cholecalciferol, 2000 IU/d), visolie, uitgezaaide vormen van kanker, obese, BMI, JAMA, placebo gecontroleerde studie


Plaats een reactie ...

Reageer op "vitamin D3 (cholecalciferol, 2000 IU/d) vermindert het ontstaan van gevorderde uitgezaaide vormen van kanker. Echter bij dikke en obese mensen is er geen statistisch significant verschil"


Gerelateerde artikelen